Escend Press Release Saira Bates 6/20/24 Escend Press Release Saira Bates 6/20/24 Escend Announces Poster Presentation at the Annual Meeting of the European Hematology Association from an Investigator-Initiated Phase I/II study evaluating ES-3000 in Myelodysplastic Syndrome (MDS) Read More Escend Press Release PJ Welsch 7/15/22 Escend Press Release PJ Welsch 7/15/22 Escend Pharmaceuticals, Inc., Receives IND Clearance from the FDA for ES-3000 Phase I Study in Relapsed or Refractory Acute Myeloid Leukemia (AML) Read More PJ Welsch 12/28/16 PJ Welsch 12/28/16 Escend Pharmaceuticals, Inc., Receives Second Orphan Drug Designation from FDA for ES-3000 Read More PJ Welsch 6/2/16 PJ Welsch 6/2/16 Escend Pharmaceuticals, Inc. Receives Orphan Drug Designation from the US Food and Drug Administration (FDA) for ES-3000, its Lead Compound, in the Treatment of Chronic Myeloid Leukemia (CML) Read More
Escend Press Release Saira Bates 6/20/24 Escend Press Release Saira Bates 6/20/24 Escend Announces Poster Presentation at the Annual Meeting of the European Hematology Association from an Investigator-Initiated Phase I/II study evaluating ES-3000 in Myelodysplastic Syndrome (MDS) Read More
Escend Press Release PJ Welsch 7/15/22 Escend Press Release PJ Welsch 7/15/22 Escend Pharmaceuticals, Inc., Receives IND Clearance from the FDA for ES-3000 Phase I Study in Relapsed or Refractory Acute Myeloid Leukemia (AML) Read More
PJ Welsch 12/28/16 PJ Welsch 12/28/16 Escend Pharmaceuticals, Inc., Receives Second Orphan Drug Designation from FDA for ES-3000 Read More
PJ Welsch 6/2/16 PJ Welsch 6/2/16 Escend Pharmaceuticals, Inc. Receives Orphan Drug Designation from the US Food and Drug Administration (FDA) for ES-3000, its Lead Compound, in the Treatment of Chronic Myeloid Leukemia (CML) Read More
